Johnson & Johnson signed a definitive agreement for $3.05 billion in cash to acquire Halda Therapeutics OpCoa company developing the next generation of highly specific oral therapies for various solid tumors, such as prostate cancer.
“This acquisition further strengthens our oncology portfolio with a main asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncologyproviding a potential medium- and long-term catalyst for growth,” said Jennifer Taubert, executive vice president, global president, Innovative Medicine, Johnson & Johnson.
Halda has a patented platform, Regulated Induced Proximity TArgeting Chimera (RIPTAC), designed to develop oral therapies targeting multiple types of solid tumors, it said in a statement.
The solid cancers They are those that form tumors in organs or tissues, such as the breast, lung or prostate, unlike those that affect the blood, such as leukemia.
The main candidate, HLD-0915is a therapy in the clinical phase for this disease, whose new diagnoses are estimated to reach 1.7 million worldwide by 2030.
According to the pharmaceutical company, the once-daily treatment could change outcomes for patients by offering a precision approach to killing cancer cells, capable of overcoming common mechanisms of drug resistance.
The acquisition also includes several candidates aimed at breast, lung and other tumors.
Furthermore, Halda’s platform also has the potential to create new targeted therapies beyond oncology.
Johnson & Johnson The acquisition is expected to close in the coming months, subject to antitrust clearance and other closing conditions customary for this type of transaction.
rrg
